Gravar-mail: Prospective Immune Dynamics during the First 24 Weeks of Efavirenz Based-Antiretroviral Therapy in HIV-1-Infected Subjects, According to CD4(+) T-Cell Counts at Presentation: The IMMUNEF Clinical Trial